Cosentyx (secukinumab) is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is an interleukin-17A (IL-17A) inhibitor, which works by blocking the action of a specific protein involved in inflammation [1].

Regarding vaccination, the manufacturer's prescribing information for Cosentyx does not provide specific information on common side effects associated with administering vaccines after Cosentyx treatment [2]. However, the general guidance is that live vaccines should be avoided in patients receiving biologic therapy, like Cosentyx, due to the potential risk of infection [3].

Therefore, it is recommended to consult with a healthcare provider to discuss the specific risks and benefits of vaccination while on Cosentyx therapy [3].

Cited Sources:

1. Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. Available from: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
2. Cosentyx (secukinumab) [Highlights of Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125557s033lbl.pdf>.
3. American Academy of Dermatology. Biologic therapies for psoriasis: From the patient's perspective. J Am Acad Dermatol. 2018;78(3):561-571. doi: 10.1016/j.jaad.2017.11.012.

Additional Source:

4. DrugPatentWatch. Cosentyx (secukinumab) Drug Profile. Available from: <https://www.drugpatentwatch.com/drugs/cosentyx>.